Figure 7.

The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by SUP-T1

(A) Mouse tumor burden of each treatment group at the indicated time points. The results are displayed as mean ± SEM (n = 6). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 (two-way ANOVA). (B) Growth and staging of the tumor monitored by bioluminescence imaging are shown. (C) Relative frequency of CD5KO anti-CD5 CAR-T cells (CD45⁺ EGFR⁺) in peripheral blood of mice on day 13, day 20, and day 26, respectively (n = 6). (D) Overall Kaplan-Meier survival curve is shown. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 (log rank test).